

### Remarks

This REPLY is in response to an Office Action mailed June 2, 2005. The Examiner issued another Restriction Requirement and requested an Election of Species. Applicants herein elect group I claims, claim 3 for prosecution in this application. Applicant notes that claims 1, 2, 5-7 and 9-11 link inventions I, II and III. If a linking claim is allowed, the restriction of inventions I, II and III will be withdrawn, and claims in those inventions will be rejoined into this application. Applicants herein withdraws claims 21-22, being drawn to non-elected inventions and reserve the right to prosecute those claims and/or others in continuing or divisional applications.

Applicants herein elects the species of IGF-1 to be (1-3) IGF-1 ("Gly-Pro-Glu;" "GPE") and elects the species of angiotensin converting inhibitor to be captopril.

Applicants believe that all the claims in this case are allowable, and urge the Examiner to consider the patentability of the claims and find the claims allowable.


Included with this Response is a Petition for Extension of time for five (5) months.

If the Examiner believes that a conversation with the undersigned would move this application forward, the undersigned Attorney invites such a conversation.

The Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 06-1325 for any matter in connection with this response, including any fee for extension of time, which may be required.

Respectfully submitted,

Date: November 10, 2005

By:   
D. Benjamin Borson, Ph.D.  
Reg. No. 42,349

Customer No. 23910  
FLIESLER MEYER LLP  
Four Embarcadero Center, Fourth Floor  
San Francisco, California 94111-4156  
Telephone: (415) 362-3800